JP2025515491A - ミオシン阻害剤の投与方法 - Google Patents

ミオシン阻害剤の投与方法 Download PDF

Info

Publication number
JP2025515491A
JP2025515491A JP2024563614A JP2024563614A JP2025515491A JP 2025515491 A JP2025515491 A JP 2025515491A JP 2024563614 A JP2024563614 A JP 2024563614A JP 2024563614 A JP2024563614 A JP 2024563614A JP 2025515491 A JP2025515491 A JP 2025515491A
Authority
JP
Japan
Prior art keywords
patient
dose
mavacamten
treatment period
lvot
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515491A5 (enExample
Inventor
ブイ ペレラ，ヴィディア
メラリ，サミラ
セーナート，エイミー
チャン，マイケル
セト，デューイ
ロックマン，ジェフリー
パピ，マリー－ロール
Original Assignee
マイオカーディア，インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マイオカーディア，インク filed Critical マイオカーディア，インク
Publication of JP2025515491A publication Critical patent/JP2025515491A/ja
Publication of JP2025515491A5 publication Critical patent/JP2025515491A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/06—Measuring blood flow
    • A61B8/065—Measuring blood flow to determine blood output from the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024563614A 2022-04-26 2023-04-25 ミオシン阻害剤の投与方法 Pending JP2025515491A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263335209P 2022-04-26 2022-04-26
US202263335028P 2022-04-26 2022-04-26
US63/335,209 2022-04-26
US63/335,028 2022-04-26
US202263336254P 2022-04-28 2022-04-28
US63/336,254 2022-04-28
PCT/US2023/019710 WO2023211872A1 (en) 2022-04-26 2023-04-25 Methods of administering myosin inhibitors

Publications (2)

Publication Number Publication Date
JP2025515491A true JP2025515491A (ja) 2025-05-15
JP2025515491A5 JP2025515491A5 (enExample) 2026-05-01

Family

ID=86558746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563614A Pending JP2025515491A (ja) 2022-04-26 2023-04-25 ミオシン阻害剤の投与方法

Country Status (12)

Country Link
US (4) US20230338378A1 (enExample)
EP (1) EP4514355A1 (enExample)
JP (1) JP2025515491A (enExample)
KR (1) KR20250016125A (enExample)
CN (2) CN119789856A (enExample)
AU (1) AU2023260472A1 (enExample)
CA (1) CA3249509A1 (enExample)
CL (1) CL2024003237A1 (enExample)
IL (1) IL316204A (enExample)
MX (1) MX2024013068A (enExample)
TW (1) TW202400570A (enExample)
WO (1) WO2023211872A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
PT4370116T (pt) 2021-07-16 2025-03-14 Cytokinetics Inc Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva
WO2024182469A1 (en) * 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585885B2 (en) * 2012-12-10 2017-03-07 Kissei Pharmaceutical Co., Ltd. Substituted pyrido[2,3-g]quinazolines as dopamine D2 receptor agonists
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
EP4054588A4 (en) * 2019-11-10 2023-12-13 MyoKardia, Inc. Methods of treatment with myosin modulator
MX2023002024A (es) * 2020-08-28 2023-05-10 Myokardia Inc Métodos de tratamiento con modulador de miosina.

Also Published As

Publication number Publication date
CL2024003237A1 (es) 2025-02-07
EP4514355A1 (en) 2025-03-05
CN119789856A (zh) 2025-04-08
TW202400570A (zh) 2024-01-01
US20250360132A1 (en) 2025-11-27
US20240115568A1 (en) 2024-04-11
US20250288586A1 (en) 2025-09-18
US20230338378A1 (en) 2023-10-26
CA3249509A1 (en) 2023-11-02
AU2023260472A1 (en) 2024-10-24
IL316204A (en) 2024-12-01
MX2024013068A (es) 2025-02-10
WO2023211872A1 (en) 2023-11-02
CN120549937A (zh) 2025-08-29
KR20250016125A (ko) 2025-02-03

Similar Documents

Publication Publication Date Title
JP2025515491A (ja) ミオシン阻害剤の投与方法
US20230360760A1 (en) Methods of regulating access to qsymia to mitigate potential drug-associated risks
Williams et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma
Weber‐Schoendorfer et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study
Shaddy et al. The pediatric randomized carvedilol trial in children with chronic heart failure: rationale and design
US20130101972A1 (en) Methods for reducing risk
Bello et al. Mavacamten
Bourke et al. Randomised placebo-controlled trial of combination ACE inhibitor and beta-blocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy?(DMD Heart Protection Study): a protocol study
Sarayani et al. A pharmacoepidemiologic approach to evaluate real-world effectiveness of hormonal contraceptives in the presence of drug–drug interactions
Wartna et al. Symptomatic treatment of pollen‐related allergic rhinoconjunctivitis in children: randomized controlled trial
Anderson et al. Triple therapy prevention of recurrent intracerebral disease events trial: rationale, design and progress
Deplanque et al. Drug repurposing: from the discovery of a useful pharmacological effect to making the treatment available to the patient
Shukkoor et al. Impact of clinical audit on adherence to the guidelines directed medical therapy in patients admitted with heart failure
JP2023524268A (ja) アムロジピンの投与計画
Sobhy et al. The Atrial FibriLlatiOn Registry (FLOW-AF): Patient Characteristics, Treatment Patterns, and Outcomes in Egypt
Larmer et al. Impact of pharmacist collaborative practice agreement on pharmacogenomic implementation for patients referred from geriatric medicine
Phillipi et al. Costs and outcomes associated with the administration of Intravenous Acetaminophen in neonates after esophageal atresia and tracheoesophageal fistula repair
Weatherald et al. Real-world persistence of selexipag for pulmonary arterial hypertension in Canada
TIMing randomised controlled trial
D'Angelo Targeting the Clinical Course of Hypertrophic Cardiomyopathy: Keeping a Beat on New and Emerging Therapies.
Sapkota et al. Dosage individualization proposed for anti-gout medications among the patients with gout: a bicentric study in Nepal
WO2025036839A1 (en) Soluble guanylate cyclase activators for treating clinically significant portal hypertension and decompensated cirrhosis
Bruneau et al. CRISM Protocol 001 Optimizing Patient Centered-Care: A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid
Maling et al. marc members present
Lawrence et al. Statistical Review AND Evaluation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260422